Additive and Antagonistic Effects Among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity

Authors

  • Daisuke Tsuriya Hirotoshi Nakamura Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Hiroshi Morita Hirotoshi Nakamura Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Tetsu Morioka Hirotoshi Nakamura Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Shigekazu Sasaki Hirotoshi Nakamura Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Yutaka Oki Hirotoshi Nakamura Second Division, Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

DOI:

https://doi.org/10.17140/DROJ-1-105

Keywords:

Glimepiride Telmisartan, Pioglitazone Nuclear receptor

Abstract

Objective: The Angiotensin-II receptor blocker telmisartan and sulfonylurea glimepiride may have clinical usefulness as partial agonists of PPARg. We investigated additive and antagonistic effects among combinations of telmisartan, glimepiride, and the Thiazolidinedione (TZD) selective PPARg agonist pioglitazone on transcriptional activity of PPARg. Materials/Methods: The receptors of pCMX-PPARg and pCMX-RXR, and PPRE-Luc reporter gene were transfected into CV1 cells, and treated with following agents, and luciferace assay was performed. Moreover, mammalian two-hybrid assay was done using GAL4 responsive reporter tk-MH100(UAS)×4-Luc and the chimeric receptor GAL4-PPARg. Results: Telmisartan increased transactivation of PPARg dose dependently. Activation by telmisartan 10 μM was 58.8% of that by pioglitazone 10 μM. Glimepiride also increased transactivation of PPARg dose dependently. Activation by glimepiride 10 μM was 49.8% of that by pioglitazone 10 μM. Addition of telmisartan 5 μM significantly enhanced transactivation by glimepiride 10 and 50 μM. Moreover, addition of pioglitazone 0.5 μM significantly enhanced transactivation by glimepiride 10 and 50 μM. Mammalian two-hybrid assay showed additive effect between glimepiride and telmisartan on binding of SRC-1 to PPARg. On the other hand, addition of glimepiride 10 and 50 μM reduced transactivation by pioglitazone 5 μM to 74% and 70%, respectively. Conclusion: Partial agonists of PPARg additively enhanced transactivation by other agonists, whereas high concentration of partial agonists reduced transactivation by full agonist antagonistically.

References

Tontronoz P, Hu E, Craves RA, et al. MPPAR-gamma2:tissue specific regulator of an adipocyte enhancer. Genes Dev. 1994; 8: 1224-1234. doi: 10.1101/gad.8.10.1224

Chawia A, Schwarz EJ, Dimaculangan DD, et al. Peroxi-some proliferator-activated receptor gamma (PPAR): Adipose predominant expression and induction early in aadipocyte dif-ferentiation. Endocrinology. 1994; 135: 798-800. doi: 10.1210/ endo.135.2.8033830

Wu Z, Rosen ED, Brun R, et al. Cross-regulation of C/EBPal-pha and PPARganmma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Molecular cell. 1999; 3: 151-158. doi: 10.1016/S1097-2765(00)80306-8

Gampe RT, Montana VG, Lambert MH, et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the mo-lecular basis of heterodimerization among nuclear receptors. Molecular cell. 2000; 5: 545-555. doi: 10.1016/S1097-2765- (00)80448-7

Lehmann JM, Moor LB, Smith-Oliver TA, et al. An antidi-abetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor gamma (PPAR-gam-ma). J. Biol. Chem. 1995; 270: 12953-12956. doi: 10.1074/ jbc.270.22.12953

Schupp M, Clemenz M, Gineste R, et al. Molecular character-ization of new selective peroxisome proliferator-activated recep-tor modulators with angiotensin receptor blocking activity. Dia-betes. 2005; 54: 3442-3452. doi: 10.2337/diabetes.54.12.3442

Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR modulationg activity. Hypertension. 2004; 43: 993-1002. doi: 10.1161/01.HYP.0000123072.34629.57

Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPAR by angiotensin II type 1-receptor antagonists. Vas-cular Pharmacology. 2006; 45(3): 154-162. doi: 10.1016/j. vph.2006.05.002

Imayama I, Ichiki T, Inanaga K, et al. Telmisartan downregu-lates angiotensin II type 1 receptor through activation of peroxi-some proliferator-activated receptor g. Cardiovascular research. 2006; 72: 184-190. doi: 10.1016/j.cardiores.2006.07.014

Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonists, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS let-ters. 2004; 576: 492-497. doi: 10.1016/j.febslet.2004.09.027

Nakaya K, Ayaori M, Hisada T, et al. Telmisartan enhanc-es choresterol efflux from THP-1 macrophages by activating PPARg. J Atherosclerosis Thromb. 2007; 14: 133-141. doi: 10.5551/jat.14.133

Pershadsingh HA. Treating the metabolic syndrome us-ing angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor. The International Journal of Biochemistry & Cell Biology. 2005; 766-781. doi: 10.1016/j.biocel.2005.08.006

Haraguchi T, Takasaki K. Naito T, et al. Cereberoprotective action of telmisartan by inhibition of macrophages/microglia ex-pressing HMGB1 via peroxisome proliferator-activated receptor g-dependent mechanism. Neuroscience letters. 2009; 464: 151- 155. doi: 10.1016/j.neulet.2009.08.043

Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 block-ers induce peroxisome prolifwerator-activated receptor gamma activity. Circulation. 2004; 109: 2054-2057. doi: 10.1161/01. CIR.0000127955.36250.65

Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an an-giotensin II type 1 receptor blocker, inhibits advanced glyca-tion end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through down regulation of receptor for AGEs via peroxisomme proliferator-activated receptor-g activation. J Int Med Res. 2007; 35: 482-489.

Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome prolif-erator-activated receptor-gamma activation. Diabetologia. 2006; 49: 3094-3099. doi: 10.1007/s00125-006-0437-7

Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma ac-tivation. J Hypertens. 2006; 24: 1809-1816. doi: 10.1097/01. hjh.0000242405.68461.84

Fukuen S, Iwaki M, Yasui A, et al. Sulfonylurea agents ex-hibit peroxisome proliferator-activated receptor antagonistic ac-tivity. J Biol Chem. 2005; 280: 23653-23659. doi: 10.1074/jbc. M412113200

Inukai K, Watanabe M, Nakashima Y, et al. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-g activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2005; 328: 484-490. doi: 10.1016/j.bbrc.2004.12.190

Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the proxisome proliferator-activated receptor-g. Nature. 1998; 395: 137-143. doi: 10.1038/25931

Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPAR gamma. J Biol Chem. 1998; 273: 31108-31122. doi: 10.1074/jbc.273.47.31108

Muller G, Geise K. Characterization of the molecular mode of action of the sulfonyluream glimepiride, at adipocytes. Horm-Metab Res. 1996; 28: 469-487. doi: 10.1055/s-2007-979839

Hamaguchi T, Hirose T, Asakawa H, et al. Efficasy of glimepiride in type 2 diabetic patients treated with glibenclamide. Diabetic Res Clin Prac. 2004; 66: 129-132. doi: 10.1016/j. diabres.2003.12.012

Suzuki S, Sasaki S, Morita H, et al. The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gannma2 with nuclear receptor co-repressor. J Mol Endocrinol. 2010; 45: 1-14.

Kawai K, Sasaki S, Morita H, Ito T, et al. Unliganded thyroid hormone receptor-beta1 represses liver X receptor alfa/oxyster-ol-dependent transactivation. Endocrinology. 2004; 145: 5515- 5524. doi: 10.1210/en.2004-0382

Tagami T, Yamamoto H, Moriyama K, et al. A selective pro-liferator-activated receptor- modulator, telmisartan, binds to the receptor in a different fashion from thazolidonedions. Endocri-nology. 2009; 150: 862-870. doi: 10.1210/en.2008-0502

Waku T, Shiraki T, Oyama T, et al. The nuclear receptor of PPAR gamma individually responds to serotonin- and fatty acid-metabolites. EMBO Journal. 2010; 29: 3395-3407. doi: 10.1038/ emboj.2010.197

Berger JP, Petro AN, Macnaul KL, et al. Distinct proper-ties and advantages of a novel peroxisome proliferator-activated protein selective modulator. Mol Endocrinology. 2003; 17: 662- 676. doi: 10.1210/me.2002-0217

Xu HE, Lambert MH, Montana VG, et al. Structial deter-minants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci. 2001; 98: 13919-13924. doi: 10.1073/pnas.241410198

Chujo D, Yagi K, Asano A, et al. Telmisartan treatment de-creses visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hy-pertensive patients. Hypertens Res. 2007; 30: 1205-1210. doi: 10.1291/hypres.30.1205

Pershadsingh HA, Kurz TW. Insulin-sentitizing effects of telmisartan. Diabetes care. 2004; 27: 1015. doi: 10.2337/ diacare.27.4.1015

Benndorf RA, Rudolph T, Appel D, et al. Telmisartan im-proves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006; 55: 1159-1164. doi: 10.1016/j. metabol.2006.04.013

Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated pro-tein selective modulator. Mol Endocrinol. 2000; 17: 662-676.

Derosa G, Fogari E, D’Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with meta-bolic syndrome treated with rosiglitazone. Journal of Clinical pharmacy and Therapuetics. 2007; 32: 261-268. doi: 10.1111/ j.1365-2710.2007.00820.x

Zanchi A, Dulloo AG, Perregaux C, et al. Telmisartan pre-vents the glitazone-induced weight gain wituout interfering with its insulin-sensitizing properties. Am J Physiol Endoclinol Me-tab. 2007; 293: E91-E95. doi: 10.1152/ajpendo.00024.2007

He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-acti-vated receptor-delta-dependent pathways. Hypertension. 2010; 55: 869-879. doi: 10.1161/HYPERTENSIONAHA.109.143958

Downloads

Published

2015-04-17

How to Cite

Daisuke Tsuriya, Hiroshi Morita, Tetsu Morioka, Shigekazu Sasaki, & Yutaka Oki. (2015). Additive and Antagonistic Effects Among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity. Diabetes Research, 1(2), 27–33. https://doi.org/10.17140/DROJ-1-105

Issue

Vol. 1 No. 2 (2015): Volume 1 Issue 2 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.